Business Standard

Dr Reddy's Lab rises 2.3%

Read more on:    Nordic Bioscience | Dr Reddys Lab
Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

For FIIs, India is the best in EM basket

Foreign investors are betting top dollar on the country as growth is likely to recover at a time when other emerging markets are battling ...

Markets to remain closed on account of Good Friday

It's a truncated week for Indian stock market with two public holidays this week

India Inc's m-cap nears record

Just 3% lower than the all-time peak seen in Nov 2010; IT and consumption-oriented firms move up the list, with bigger rewards for those ...

Coal India awaiting more triggers

Analysts expect it to raise prices this quarter to offset rising costs; faster clearances seen for project plans but output rise still seen as a ...

FIIs bullish on ICICI Bank; stake hits 6-year high

During quarter ended March, the stock gains 13.3% compared with the Bankex's 12% rise

Back to Top